Patient P-03167
Therapy response
Stable
Tolerance
Favorable
GI state
Favorable
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
14%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 ONX-7 started — Baseline state S18
- Day 14 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 14.
Primary contributors, last 14 days
- Treatment adherence-4
- Inflammatory activity-3
- Nutritional resilience+3
- Toxicity+2
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Energy level
Daily log6.4/10
improving · +0.5 vs previous 14 d
Stress level
Daily log4.2/10
improving · -0.4 vs previous 14 d
Pessimism score
Daily log3.9/10
improving · -0.5 vs previous 14 d
Sleep quality
Wearable63/100
improving · +3.3 vs previous 14 d
Libido
Daily log5.2/10
improving · +0.5 vs previous 14 d
HRV
Wearable62.4 ms
stable · +1.2 vs previous 14 d
Toxicity
Blood9.5/100
improving · -5.0 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading drifting · 72 from the failing basin, 26 from restoration.
Good elements to keep
- Protein (supports)perturbation · steering +9.7
- Daily walks resumedperturbation · steering +3.3
- Proteinsupporter · GI -5.6 next day
Main detractors to watch
- Low butyrate capacityhidden · steering -17.5
- FUT2 non-secretorhidden · steering -10.6
- Dietary fat loadperturbation · steering -10
- Histamine loadperturbation · steering -8.9
- Dietary fat loaddetractor · GI +5.8 next day
- Histamine loaddetractor · GI +5.2 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Dietary fat load+5.8detractor · 95%
- Protein-5.6supporter · 95%
- Histamine load+5.2detractor · 95%
- Alcohol+4.4detractor · 95%
- Lactose-0.4no signal · 15%
- Caffeine+0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Butyrate / short-chain fatty acid production ↓35
- MicrobiomeButyrate capacity 36/100
- Mucosal barrier integrity ↓30
- DNAFUT2 non-secretor lowers mucosal fucosylation
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Normal metabolizerExpected exposure
Microbiome
Shannon diversity 2.9 · butyrate capacity 36/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 65 ms
- Sleep
- 7.6 h
- Steps
- 5,646
- Resting HR
- 70 bpm
Daily log: GI score 23, nutritional resilience 62, adherence 88.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-03204 | 41% | S16 | AD-05 | improved | 48 |
| P-03369 | 40% | S18 | AD-05 | no change | 37 |
| P-03105 | 39% | S12 | AD-05 | no change | 60 |
| P-03351 | 39% | S07 | AD-05 | no change | 51 |
| P-03122 | 38% | S13 | AD-05 | no change | 40 |
| P-03424 | 36% | S12 | AD-05 | improved | 41 |
| P-03441 | 36% | S19 | AD-05 | improved | 37 |
| P-03034 | 35% | S14 | AD-05 | no change | 30 |
| P-03129 | 35% | S18 | AD-05 | no change | 32 |
| P-03380 | 35% | S16 | AD-05 | improved | 34 |
| P-03111 | 34% | S07 | AD-05 | no change | 48 |
| P-03158 | 34% | S17 | AD-05 | no change | 37 |